Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study

C. L. de Mol, Y. Y.M. Wong, E. D. van Pelt, I. A. Ketelslegers, D. P. Bakker, M. Boon, K. P.J. Braun, K. G.J. van Dijk, M. J. Eikelenboom, M. Engelen, K. Geleijns, C. A. Haaxma, J. M.F. Niermeijer, E. H. Niks, E. A.J. Peeters, C. M.P.C.D. Peeters-Scholte, B. T. Poll-The, R. P. Portier, J. F. de Rijk-van Andel, J. P.A. SamijnH. M. Schippers, I. N. Snoeck, H. Stroink, R. J. Vermeulen, A. Verrips, F. Visscher, J. S.H. Vles, M. A.A.P. Willemsen, C. E. Catsman-Berrevoets, R. Q. Hintzen, R. F. Neuteboom*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)
4 Downloads (Pure)

Abstract

Introduction: Acquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of the central nervous system in children. A nationwide, multicentre and prospective cohort study was initiated in the Netherlands in 2006, with a reported ADS incidence of 0.66/100,000 per year and MS incidence of 0.15/100,000 per year in the period between 2007 and 2010. In this study, we provide an update on the incidence and the long-term follow-up of ADS in the Netherlands. Methods: Children < 18 years with a first attack of demyelination were included consecutively from January 2006 to December 2016. Diagnoses were based on the International Paediatric MS study group consensus criteria. Outcome data were collected by neurological and neuropsychological assessments, and telephone call assessments. Results: Between 2011 and 2016, 55/165 of the ADS patients were diagnosed with MS (33%). This resulted in an increased ADS and MS incidence of 0.80/100,000 per year and 0.26/100,000 per year, respectively. Since 2006 a total of 243 ADS patients have been included. During follow-up (median 55 months, IQR 28–84), 137 patients were diagnosed with monophasic disease (56%), 89 with MS (37%) and 17 with multiphasic disease other than MS (7%). At least one form of residual deficit including cognitive impairment was observed in 69% of all ADS patients, even in monophasic ADS. An Expanded Disability Status Scale score of ≥ 5.5 was reached in 3/89 MS patients (3%). Conclusion: The reported incidence of ADS in Dutch children has increased since 2010. Residual deficits are common in this group, even in monophasic patients. Therefore, long-term follow-up in ADS patients is warranted.

Original languageEnglish
Pages (from-to)1310-1319
Number of pages10
JournalJournal of neurology
Volume265
Issue number6
DOIs
Publication statusPublished - 1 Jun 2018
Externally publishedYes

Keywords

  • UT-Hybrid-D
  • Children
  • Epidemiology
  • Multiple sclerosis
  • Outcome
  • Acquired demyelinating syndromes

Fingerprint Dive into the research topics of 'Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study'. Together they form a unique fingerprint.

  • Cite this

    de Mol, C. L., Wong, Y. Y. M., van Pelt, E. D., Ketelslegers, I. A., Bakker, D. P., Boon, M., ... Neuteboom, R. F. (2018). Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study. Journal of neurology, 265(6), 1310-1319. https://doi.org/10.1007/s00415-018-8835-6